**BrainQ technologies- BIOMED 2023**

1. **Investment Rational**

BrainQ has developed a cloud-based bioelectric therapy, ENTF, promotes neuronal network recovery post ischemic stroke by modulating brainwaves related to the plasticity window. The FDA has granted breakthrough designation to this wearable device following promising results in a pilot study. BrainQ is approaching interim results of the EMAGINE Stroke Recovery Trial run across top academic sites in US

1. **Business Strategy**

After completing its pivotal study, the company intends to distribute its technology as a Durable Medical Equipment (DME), starting in the US and expanding to Asia and the EU. To achieve this, the company is generating awareness within the clinical community and engaging in ongoing discussions with strategic partners for commercial distribution.

1. **Core Technology**

Our Novelty in leveraging advanced AI tools to derive network targeting therapies based on insights from the brainwaves. In addition, the technology offers a scalable continuum of care, via cloud connected therapy, that allows treating patients throughout their recovery journey.

1. **Product Profile/Pipeline**

The potential of neuro recovery is enormous, particularly given the increasing age of the world's population. Company’s pipeline further includes AD, MS and TBI

1. **What’s Next?**

Company’s main focus is on executing its pivotal study across the US, while establishing itself as a category leader for home recovery therapeutics.